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The lymphatic system is an essential but often understudied in comparison with its car-
diovascular counterpart. Such disparity could often be explained by the lack or complexity
of the existing imaging and analysis techniques available for the quantification of lymphat-
ics compared to the ones available for the blood vasculature. An additional challenge is
the absence of representative in vivo models that efficiently replicate the lymphatic dys-
function observed in humans. Those factors motivate the continuous investigation of novel
models for lymphatic diseases and ways to evaluate the overall function of the lymphatic
system. Recently, it has been shown that verteporfin, a photosensitive drug widely used
for photodynamic therapy (PDT) to ablate the blood vessels, provides a similar effect on
lymphatic vessels. Here, we seek to administer verteporfin and perform PDT of collecting
lymphatics in the mouse tail, which is a commonly used location for the study of lymphatic
disorders and examine lymphatic remodeling, contractility, and transport in response to the
procedure. To quantify the induced changes, the lymphatic function was evaluated using a
near-infrared (NIR) imaging system. Additional image processing has been introduced to
access the NIR tracer distribution following the lymphatic injury caused by the verteporfin
administration. As a result, we are able to increase lymphatic permeability noninvasively
at the targeted area. This technique has the potential to be a stand-alone procedure to in-
vestigate the lymphatic response to a localized leakage and reactive oxygen species (ROS)




The lymphatic system is a network of lymphatic vessels and lymphoid organs, distributed
around the body, that plays a major role in lipid transport [1], fluid homeostasis [2] and
immune cell trafficking [3]. The lymphatics unidirectionally transport lymph, a fluid con-
taining proteins, from interstitial space back to the blood circulation [4]. While in the
cardio-vascular system the heart is the central pump for blood transport, propagation of the
lymph is not driven by a single centralized pump. Instead, a combination of external tis-
sue pressures and an internal pump mechanism driven by contractions of lymphatic muscle
cells, are responsible for lymph movement. The lymphatic system transfers 4-8 liters of
fluid back into the blood stream daily through the collecting ducts [5] and it is estimated
that as much as 12 liters of lymph per day is returned in total to the circulation when one
also considers fluid absorption into the venous circulation at regional lymph nodes. The
whole system can be considered as fluid storage of filtered plasma [2].
1.1 Lymphatic physiology
The lymphatic system can be divided into several units: initial lymphatics, collecting lym-
phatics, and lymph nodes[4]. Initial lymphatics are blind-ended vessels or plexus of vessels
in peripheral tissues that allow for free diffusion of solutes within them. This is also the
site of lymph formation, where fluid enters the lymphatics. Initial lymphatics, or capillar-
ies, are composed of a monolayer of lymphatic endothelial cells (LECs) with no basement
membrane [2]. Anchoring filaments connect the extracellular matrix to the lymphatic en-
dothelial cell cytoskeleton via transmembrane α3β1 integrin and focal adhesion kinase
(FAK) [2, 6, 7]. Anchoring filaments are supporting the attachment of the lymphatic wall
to the surrounding tissues [8] and are thought to facilitate fluid entry into the initial vessel
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lumen when the surrounding tissue expands.
From initial lymphatics, lymph is drained to pre-collecting and collecting lymphatic
vessels (CLVs). Collecting lymphatics organization resembles a binary tree, while the ini-
tial lymphatics represent a system of fractals, which cover large areas of the tissue [9]. The
pre-collecting lymphatics have one-way valves, but lack lymphatic muscle, and sometimes
appear between initial and collecting lymphatics [10]. Meanwhile, collecting vessels are
surrounded by lymphatic muscle cells (LMCs) with the lumen of the vessel aligned with
LECs, and contain bicuspid valves to prevent backflow [11, 12]. LMCs of the lymphatic
vessels are highly contractile, regulating both vessel tone as well as driving the phasic con-
tractions responsible for flow generation. Lymphatic vessels are divided into individual
contractile units, termed lymphangions, which are separated by the valves and facilitate
unidirectional flow [13].
Afferent collecting lymphatics carry the lymph to the lymph nodes. This lymph from
the peripheral tissues contains antigens and antigen-presenting cells (APCs) from the down-
stream tissue and is important in facilitating local responses to infection as well as estab-
lishing self-tolerance [14]. Lymph undergoes significant modifications in lymph nodes due
to the interactions of APCs with T-cells and due to hydrostatic and osmotic forces present in
the lymph node capillaries [2, 15, 16]. As a result, the post-nodal lymph exiting the efferent
collecting vessel has a higher count of lymphocytes [15] and proteins[16], while lacking
APCs, most of which remain in the lymph node to present antigen to T-cells [17]. Efferent
lymphatics carry the post-nodal lymph into the larger lymphatic trunks, e.g. thoracic duct,
discharging fluid into the subclavian veins [18].
Movement of the lymph is facilitated by intrinsic and extrinsic forces [19, 20]. Intrin-
sic forces are generated by the contractions of the individual lymphangions [20], while the
extrinsic forces induced by skeletal and other muscle contractions during physical move-
ments, respiration, heart contractions, and intestinal motility [21, 22]. Such a system allows
transporting the fluid from the limbs to the torso against the gravitational force and, under
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normal conditions, prevent fluid accumulation in the interstitium [22].
Lymphatic endothelial cells are distinguished from blood endothelial cells in part by the
expression of vascular endothelial growth factor receptor-3 (VEGFR3), the receptor that
binds the growth factors VEGF-C and VEGF-D, which facilitate lymphangiogenesis [23,
24]. In addition, compared to blood endothelial cells LECs also express podoplanin [25],
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) [26] a lymphatic-specific
receptor for hyaluronan and prospero homeobox protein 1 (Prox-1), a transcription factor
that play a key role in maintaining LEC identity [27].
LECs are connected through cell-to-cell junctions that are specialized depending in
which part of the lymphatics they are present within: initial or collecting. In initial lym-
phatics, the cells possess junctions that have been described as “button-like”, while in
collecting vessels, they have a “zipper-like” phenotype. Different organization of cell-
junction proteins creates these structures and facilitates fluid uptake from the interstitium
into initial lymphatics and prevents its leakage from the CLVs. An adhesive protein vas-
cular endothelial cadherin (VE-cadherin) along with several tight junction proteins com-
prise the “buttons”, which alternate with the PECAM-1 (platelet/endothelial cell adhe-
sion molecule-1) expression [28]. “Zippers” contain junctions that are similar to those
found in veins, achieved through the continuous expression of VE-cadherin [29]. It was
shown, that under the influence of elevated transmural flow, VE-cadherin and PECAM-1
were down-regulated and relocalized [30] which is thought to facilitate immune cell en-
try to initial lymphatics during inflammation. During the maturation of lymphatic vessels,
zipper-to-button junction transformation occurs in initial lymphatics, while depletion of
Angiopoietin-2 (Agn2) leads to leaky collecting vessels and impaired lymph uptake [31].
Thus the organization of junctional molecules within lymphatics is a dynamic process that
has implications on both lymphatic development and the regulation of lymphatic perme-
ability in health and disease.
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1.2 Permeability
Lymphatic endothelial cells in initial lymphatics accommodate interstitial fluid absorption
and keep the absorbed liquid within the vessel when interstitial pressure is below hydro-
static pressure within the lymphatic lumen. Chemical and physical factors, such as those
that are elevated in high fat diet-induced obesity animal models, can account for increased
permeability of the lymphatic vessels due to the change in the shape and cell junctions
between the lymphatic endothelial cells [30, 32].
Lymphatic capillaries are highly permeable; therefore, the protein concentration of
interstitial fluid is the same as the local initial lymphatics and there is minimal oncotic
pressure gradient across the vessel wall. This observation is also true for the low-density
lipoprotein (LDL) and high-density lipoprotein (HDL) levels in the peripheral tissues [33].
The collecting lymphatics are permeable to fluid and proteins (i.e., albumin) at a similar rate
as venules [13, 34]. Thus there exists a small leakage of lymph from collecting lymphatic
vessels due to the balance of Starling’s forces (i.e. there is a minimal protein concentration
gradient and larger transmural pressure compared to the initial lymphatics that favors fluid
exit from the vessel and serves to concentrate lymph). However, this phenomenon does
not affect the lymph transport to the lymph nodes, since only a small fraction of the liquid
leaks into the interstitium under normal conditions [34].
However, this can change in pathologies such as cancer. Cancer induces not only an-
giogenesis through VEGF, but also lymphangiogenesis by production of VEGF-C, which
forms leaky and disorganized blood and lymphatic vessels with abnormal function [35,
36]. This also promotes the migration of macrophages and leads to advancement of tumor
metastasis [37, 38]. Leaky lymphatics are also associated with various disorders, such as
atherosclerosis, obesity, and metabolic disorder type 2 diabetes mellitus [39]. Since adi-
pose tissues are collocated around lymph nodes and collecting vessels, it was suggested,
that lymphatics are permeable to lipids as well as to proteins [40]. Permeability of col-
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lecting lymphatic vessels causes inflammation in prenodal adipose tissue (PAT) induced
by inflammatory stimuli from the lymph and lymph-derived antigen presentation to the lo-
cal PAT DC [41]. Conversely, obesity may induce lymphatic leakiness due to the chronic
inflammation [42, 43, 44, 45, 46]. Furthermore, development of edema in the case of
lymphatic obstruction or following a mechanical, chemical or thermal stimulus, has been
associated with the increased permeability of the lymphatic wall [47].
Nitric oxide (NO) has a dual role in regulation of lymphatic permeability, depending on
the state of the vessel. In wild-type collecting lymphatics NO increased the permeability,
whereas in vessels from type 2 diabetes animals initial lymphatic barrier dysfunction was
restored to normal [39].
Various inflammatory cytokines are known to increase permeability in blood vascular
endothelial cells and for some their effect on lymphatic endothelial cells has been studied
in-vitro. Specifically, cytokines TNF-α, IL-6, Th1-associated cytokines IL1-β, IFN-γ, and
LPS all increased the permeability of an LEC monolayer grown on transwells [48]. Other in
vitro studies performed on human dermal LECs treated with TNF-α for 24 hours revealed
change in VE-cadherin distribution at the cell periphery and increased number of discon-
tinuous cell junctions [49]. Inflammation also promotes lymphatic vessel enlargement and
leakiness, while stimulation of the lymphatic vasculature with exogenous VEGF-C admin-
istration decreased this pathology in animals with rheumatoid arthritis [50]. At the same
time, overexpression of VEGF-C leads to inflammatory macrophage chemotaxis and in-
creased permeability [50, 51].
A few studies measuring lymphatic permeability in vivo revealed decreased lymphatic
function, leakiness and up-regulation of VEGF-A upon UVB irradiation [52]. Most stud-
ies of lymphatic permeability have been conducted in vitro, and currently there are limited
tools to induce spatially and temporally controlled alterations in lymphatic permeability.
Inflammatory cytokines appear to be the most influential factors in increased lymphatic per-
meability together with neo-vascularization in tumors due to the overexpression of VEGF-
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C [35, 36].
Thus, regulation of lymphatic permeability requires further research, including new
approaches and animals models to quantify spatio-temporal fluctuations in lymphatic per-
meability over time.
1.3 Lymphedema
Lymphedema represents a group of pathological conditions, which manifest themselves as
an excessive accumulation of interstitial fluid, caused by reduced lymphatic transport [53].
Such buildup of the protein-rich liquid causes inflammation, fibrosis, and adipose tissue
formation [54]. Based on its origin, lymphedema can be primary or secondary [53].
Primary lymphedema may present itself at any point in life, from infancy to adoles-
cence. It can be further classified based on the time it has been recognized: congenital
lymphedema manifests itself within the first two years, while lymphedema praecox is diag-
nosed to patients undergoing puberty or in their 20s. However, primary lymphedema can
also develop after 35 years and then commonly referred to as lymphedema tarda [53]. This
type of lymphedema is rather rare, with an incidence of 1:100,000 across the globe [55].
Certain gene mutations are involved in the development of primary lymphedema. Muta-
tions in the gene FOXC2 results in abnormal smooth muscle investiture surrounding the
initial lymphatics and manifests in lymphedema distichiasis. Lymphedema distichiasis is
characterized by lymphatic dysfunction, swelling of the limbs together with distichiasis, or
extra set of eyelashes on the inner lining of the eyelid present at birth [56, 57] . Mutation
of genes encoding VEGFR3 or VEGF-C results in Milroy disease, causing fluid retention
due to either impaired fluid uptake by initial lymphatics or issues related to the lymphatic
valve structure and functionality [58, 59, 60].
Secondary lymphedema is observed more frequently than primary. It occurs as a con-
sequence of previous injury or obstruction of the lymphatic vessels, although there is some
evidence that there may be an underlying genetic predisposition to developing secondary
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lymphedema. Such lymphatic damage may be caused by filariasis, a parasitic infection, or
as a result of injury, often initiated by lymph node dissection during the cancer treatment
surgery or radiotherapy [55].
Lymphatic filariasis is a parasitic nematode infection responsible for most of the lym-
phedema cases worldwide. Approximately 120 million people are affected by this parasite
in 83 countries, most of which are in tropical climate [61] and like wide-spread vector
control. Mosquito vectors serve for larvae development and transmission to the human.
First-stage larvae (microfilaria) from the blood is taken by the vector, in which it develops
to infective larvae. Those larvae are transferred to the human host through the site of the
vector bite and travel to the lymphatic vessels, where they grow into adult filarial parasites,
which are able to reproduce for about 8 years [62].
The prevailing cause of secondary lymphedema in developed countries is cancer treat-
ment. Nowadays, about 49% of cancer patients will be affected by secondary lymphedema
following their cancer therapy [55] Radiotherapy, chemotherapy obesity, and lymph node
resections, aimed to prevent the spread of the metastasis, are all positively correlated with
increased lymphedema risk [63, 64].
Lymphedema is associated with significant changes in the local tissue environment.
Since lymphatics are responsible for immune cell trafficking, impaired functionality re-
sults in the infiltration of macrophages, dendritic cells (DCs), and neutrophils at the site of
lymphedema [44], resulting in chronic inflammation that drives tissue remodeling, reten-
tion of fat, development of fibrosis [42, 43, 44, 45, 46]. Local pressure changes often occur
in the interstitium, resulting in impaired lymphatic filling. Another outcome of inflamma-
tion is enlargement of lymphatic vessels and their dysfunction [65, 66]. However, others
have reported thickening of the lymphatic vessel wall, hyperpoliferation of lymphatic mus-
cle cells, phenotypic “lymphoscleoris” or the narrowing of the vessel lumen due to this
remodeling [67, 68].
Reduced lymphatic function, lymphatic remodeling and dilation of lymphatic vessels
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could be caused by the inflammatory response of subsets of CD4+ T-cells, such as Th9,
Th1, and Th17, Th2 cells [43, 69, 70]. Produced cytokines, such as IFN-γ and TNF-α
have a potential to stimulate nitric oxide and, therefore, facilitate the progression of the
lymphedema [69].
Furthermore, researchers have shown an increased count of regulatory T cells in the
lymphedema limb in comparison with contralateral tissue in breast cancer patients [71]. A
murine model of lymphedema, created through axillary lymph node dissection, revealed
that upregulation of Tregs distal from the surgical site results in local immunosuppression,
reduced tissue inflammation and inhibited lymphatic function. Depletion of the Tregs in
this model restored the immune response in the local tissues [71].
Macrophages also increase following the ligation of lymphatic vessels in mouse mod-
els of disease. These cells also preferentially differentiate into M2 macrophages, which
produce anti-inflammatory cytokines, and VEGF. However, the depletion of macrophage
populations in lymphedema models also increased fibrosis and reduced lymphatic func-
tion. Additionally, VEGF-C expression was decreased and accumulation of CD4+ cells
was observed [72].
While advances regarding the basic biology and immunology of lymphedema under-
standing has been limited primarily to preclinical animal models, current lymphedema
treatment aims to prevent further progression through manual therapy, and lifelong treat-
ment is required to manage the condition. One such treatment is a specialized form of
massage referred to as manual lymphatic drainage (MLD). MLD therapy seeks to move
fluid from the limbs and periphery to the torso via application of external pressure along
lymphatic drainage basins with the motivation of moving interstitial fluid from an area of
impaired lymphatic drainage to one where lymphatics are still functional [73].Compression
garments are used to prevent fluid accumulation in arms and legs for an extended period of
time [74]. Those procedures, together with physical exercise, comprise a daily routine of
the lymphedema patients [75] and while helpful, patients remain desperate for a cure.
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As there is no lymphedema cure available now, animal models are essential tools for
understanding the disease and establishing the framework to discover a remedy.
1.4 Current animal models
Several animal models have been developed to replicate lymphedema and other lymphatic
injuries and to further study this pathology and the remodeling of the lymphatic vascula-
ture. The most frequently used animals for such studies are mice and rats. Those models
can be divided into two groups: surgical and transgenic. Transgenic mouse models in-
volve the embryonic of post-natal deletion of genes important in lymphatic development
and maintenance. Examples of such models are the FLT4-DTR mouse expresses human
diphtheria receptor (DTR) on its LECs, coupled to the lymphatic promoter FLT4 allows to
ablate the lymphatics using the diphtheria toxin [76], K14-VEGFR-3-Ig mice (sR3 mice),
where chimeric protein under a keratin-14 promoter secretes soluble VEGFR3 to neutralize
VEGF-C and VEGF-D, inhibiting formation of the dermal lymphatic vessels [77], Prox1
haploinsufficient mice (Prox1+/-) [78], Chylous ascites-3 mutant mice (Chy-3) have de-
pletion in chromosome carrying Vegfc and develop dermal lymphatic hypoplasia, penile
and hind paws lymphedema [79]. Prox1 haploinsufficient mice that survive post-natal de-
velopment (many die in utero or shortly after birth) develop obesity and have increased
lymphatic permeability with the lymph leakage into the interstitium [42, 43, 44, 45, 46].
Several procedures are used to surgically induce lymphedema, particularly in rodent
tails. Collecting vessels are present on both sides of the mouse’s tail [80] and drain lymph
from the tail to the external sacral lymph node [81]. To create lymphedema, a tail inci-
sion is performed, the collecting lymphatic vessels are cut and cauterized to create a flow
blockage, and a gap of 2-3 mm in the skin is created to delay wound repair [82, 83], re-
sulting in a highly repeatable swelling of the tail and pathology similar to lymphedema.
The tail swelling and fluid accumulation are accompanied by increased lipid deposition
and reduced collagen density in dermis a day after the incision, restored by day 14. At the
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same time, hypodermis remains swollen, and its collagen density is elevated until, unlike
clinical lymphedema, the pathology and swelling is restored by day 30 [82]. An alteration
to this model was developed in which only one of the two collecting vessels is surgically
damaged. This alteration allows one to study the adaptation and functional changes of the
intact vasculature over the course of swelling [80]. Further models, while not an exhaustive
list, include axillary lymph node dissection [84], hindlimb popliteal lymph node removal
in sheep [85], and segmental resection of lymphatic vessels performed at the base of the
rabbit ear [86].
Invasive models closely represent secondary lymphedema when the pathology is in-
duced by surgery or injury. Lymphatic hyperplasia and dilation, abnormal lipid accumula-
tion due to the leaky lymphatics and backflow, which have been observed in surgical mod-
els, leads to decreased lymphatic transport [82, 86]. Fibrosis develops in the subcutaneous
and adipose tissues [46, 76]. Surgical animal models are acute due to the instantaneous
response to the injury and usually self-resolve. Thus, they do not accurately represent the
onset of human secondary lymphedema, which usually develops in months or years fol-
lowing the intervention and is a lifelong condition [55]. Therefore, the major disadvantage
of secondary lymphedema models is the spontaneous resolution of the induced condition
[87].
Surgical models do not only interrupt initial and collecting lymphatics, or remove the
lymph node, but they also damage other local tissues. For that reason, the local immune
response represents not only the lymphedema associated changes, but also consequences
of tissues disruption. Novel animal models are required to understand the precise lym-
phedema pathology and chronology of its development. In addition, less invasive models
are also needed to study the normal post-natal lymphangiogenic repair process and to un-
derstand when this process is adequate to return tissue homeostasis. To further investigate
changes in lymphatic function upon localized injury, we propose to utilize a non-invasive
photodynamic therapy approach, which preserves the skin integrity and targets the lym-
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phatics, thus the use of this approach in different physiologic contexts both clinically and
in mouse models is discussed further.
1.5 Photodynamic therapy. Verteporfin
Photodynamic therapy (PDT) is a clinical procedure, performed with the use of photosen-
sitive drug and activating light. Once combined, this produces reactive oxygen species
(ROS) and destroys targeted tissues, resulting in blood vessel occlusion [12]. Currently
PDT is most commonly used clinically to treat various ocular neo-vascularization-related
conditions, in particular age-related macular degeneration (AMD) [88]. Besides this, PDT
is used to treat selected types of cancer, psoriasis and other dermatological conditions [89,
90, 91, 92].
Verteporfin is a photosensitive drug used in photodynamic therapy. It is a lipophilic
molecule and is available on the market in a liposomal formulation, under the trade name
Visudyne R© (Visudyne R©, Novartis Ophthalmics, Hettlingen, Switzerland). In Visudyne R©,
the active ingredient is encapsulated in liposomes, formulated with lactose, egg phos-
phatidylglycerol, dimyristoyl phosphatidylcholine, ascorbyl palmitate and butylated hy-
droxytoluene [93, 94]. This liposomal formulation was designed to increase the circulation
of the drug upon IV delivery and slow its clearance.
1.5.1 Method of action
Being a two-stage process, photodynamic therapy requires not only administration of the
drug, but also application of nonthermal red light. In photodynamic therapy, the photo-
sensitizer absorbs the light energy and changes its ground singlet state S0 to excited singlet
state S1. Excited triplet state T1 arises from S1 by intersystem crossing. In a type I reaction,
it can directly induce photochemical reactions by generating cytotoxic free radicals, such as
superoxide anions O2(−), hydroxyl radicals, hydrogen peroxide. In a type II reaction, the
energy is transferred to the ground state oxygen triplet oxygen (3O2), forming excited state
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singlet oxygen (1O2). This singlet oxygen causes photooxidation of the biological tissues.
Both reactions may be present during the PDT, however singlet oxygen is considered to be
the primary mechanism of the PDT induced damage, targeting enzymes, nucleic acids and
causing cell death [95, 96].
Verteporfin has a wide absorption spectrum with multiple peaks (Figure 2.1). Clinically
the wavelength used for excitation has been 689 nm, as this wavelength occurs near the
optical window of tissues and can penetrate human skin to a depth of 5 mm, while 400
nm wavelength light reaches only 1 mm under the skin surface. This window is created
due to the lower absorption of water, oxygenated, and deoxygenated hemoglobin at the
wavelength range of 650 – 1350 nm [97, 98, 99].
1.5.2 Cell and tissue damage
Photodynamic therapy related damage occurs on several levels: cellular, immunological
and vascular [95]. As it was mentioned before, immediate cellular destruction occurs due
to generation of reactive oxygen species (ROS) [100]. The short lifetime of those oxygen
molecules limits the damage to the exact area of the light activation, while keeping the
surrounding tissues intact [95]. It has been suggested, that during PDT cells are more
likely to undergo necrosis, if the photosensitizer is localized in the plasma membrane; and
apoptotic cell death if the drug accumulates in mitochondria [89].
Vascular endothelium damage, particularly in intraluminal endothelial membranes is
observed. This causes cytoskeletal structural rearrangement and endothelial cells shrink-
ing. Following this, platelet binding is triggered due to the exposed vascular basement
membrane. Consequently, histamine, tumor necrosis factor–α (TNF-α) and thromboxane
are released by the activated platelets. This cases thrombosis, increased vascular perme-
ability and vasoconstriction as well as further platelet activation. As a result, tissue suffers
eventual hypoxia due to the blood flow stasis. Cytokine activity may also contribute to the
blood vessel ablation, but another PDT effect on the immune system is reduced activity of
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APCs at the low levels of the photosensitizer and light [95].
1.5.3 Previous studies of verteporfin effect on lymphatic vessels
Verteporfin effect on the lymphatic vessels has been investigated in a few studies. Due
to its lipophilicity, verteporfin forms complexes with low-density lipoproteins (LDL) in
blood stream and is preferentially taken up by endothelial cells through receptor-mediated
endocytosis using low-density lipoprotein receptors (LDLR) [98, 101]. It has also been
show, that LDLR is expressed on LECs of the collecting lymphatic vessels [102]. This
property provides an opportunity for lymphatic vessels to be ablated similarly to the blood
vessels, provided an appropriate method of delivery is used that targets lymphatic vessels.
One such approach is to deliver the liposomal formulation of verteporfin (Visudyne R©) via
an interstitial injection under the skin as lymphatics actively drain large molecules from
this area.
Upon light activation of the verteporfin, lymphatic endothelial cells undergo autophagy
at low light doses of PDT and apoptotic cell death at higher doses [100]. Therefore, de-
cellularization of the lymphatic vessel and basement membrane leads to their ablation and
blockage of the transport of the lymph nodes [12, 103, 104].
Lymphatic vessels facilitate immune signaling and are involved in spreading of tumor
metastasis even after the primary tumor is removed, as some tumor cells stay in the lym-
phatic vessels. In the first study, verteporfin was investigated as a potential method to
destroy collecting lymphatic vessels associated with cancerous tumor and thus limit metas-
tasis [103].
Cancer cells, which were implanted into the tip of the mouse ear, develop in-transit
tumor nodules. Visudyne R© was administrated intradermally in the ear periphery and was
taken up by the lymphatics in the mouse ear, retained within the collecting lymphatics for 2
hours and eliminated from the ear skin within 48 hours following the injection. Application
of non-thermal laser radiation of 689 nm at 3 to 5 mm from the injection site resulted in
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fragmentation and death of lymphatic endothelial and smooth muscle cells. Following the
procedure, dextran of high molecular weight was shown to leak out of the vessels, while
control mock injection and irradiation did not lead to any changes. Following the PDT in
the healthy mouse ear, no spontaneous regeneration of lymphatic vessels was detected dur-
ing the 12-month observation, unless adenoviral delivery of VEGF-C was given to enhance
regrowth [103]. However, lymphangiogenic factors released by the tumors could miti-
gate the PDT effectiveness in metastasis prevention [35, 36, 103]. Researchers examined
the metastasis following the photodynamic treatment alone and coupled with an adenovi-
rally expressed VEGFR-3 ligand trap (AdVEGFR-3-Ig) which inhibits lymphangiogenesis
[103]. It was shown that the photodynamic therapy in combination with inhibition of lym-
phangiogenesis, prevented metastasis and transport of tumor cells though the lymphatic
system. The ability of the photosensitizer to be taken up and retained in smaller lymphatic
vessels causes less damage to the surrounding tissues, than occurs during surgery, making
PDT an advantageous alternative to the surgical methods in cancer therapy. Preoperative
photodynamic therapy of the mice flank in melanoma-bearing mice prevented metastasis
and relapse in comparison with the control group, which did not undergo photodynamic
therapy. Studies were also conducted in the pig knee, where termination of lymphatic
drainage induced by the verteporfin was observed but required invasive delivery of a laser
catheter to conduct the light activation. Liposomal verteporfin dosages used in these studies
were 2 to 3 µl or 5 to 10 µl. Ophthalmological laser Zeiss Visulas 690S form Carl Zeiss
Meditech or 680 nm red diode laser (Applied Optronics) were used to deliver light dose at
50 or 72 J/cm2 at intensity of 600 mW/cm2 [103].
Another study has shown that the light dose influences the lymphatic recovery time,
while the drug dosage allowed one to target either both lymphatics and blood vessels or
only lymphatics. In this study a light dose of 3.6 J/cm2 blocked lymphatic drainage for
about 1 week, with 25 J/cm2 of light delivered the restoration took up to 3 weeks, while
no adverse effects on blood vessels was present for either case. At the same time, the use of
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0.4 J/cm2 led to increased lymphatic permeability, but it did not occlude the vessel. The
use of 100 ng verteporfin dose led to the destruction of both blood and lymphatic vessels.
At the same time, the application of 25 ng and lower only showed effects on lymphatic
vessels in the mouse ear dermis [12].
Finally, evaluation of the antitumor efficacy of verteporfin treatment in combination
with antilymphangiogenic factors has been conducted. It was shown that elimination of the
tumor associated lymphatics interfered with the development of anti-tumor immunity due
to the decreased transport of the antigen-presenting DCs to the lymph nodes [105].
1.6 Lymphatic imaging techniques
Research of the lymphatic system has been complicated due to limited imaging options,
which allow for non-invasive imaging with sufficient sensitivity and temporal resolution to
distinguish lymphatic vessels [106]. Lymphangiography has been conducted since the early
1950s using radiopaque materials subcutaneously injected, taken into the small lymphatic
vessels and imaged using X-ray. Similar approaches using labeled and contrast-enhanced
tracers were developed for radiation-based imaging, such as computed tomography (CT)
and positron emission tomography (PET) or PET-CT and single-photon emission computed
tomography (SPECT) [107]. Magnetic resonance imaging (MRI) for the lymphatics imag-
ing has also been developed. MR lymphangiography (MRL) has a potential in diagnosis
or pre-procedure planning for the central lymphatic system (cisterna chyli, thoracic duct)
[108]. MRL with subcutaneous injection of gadolinium provides an effective approach
for imaging the lower extremity lymphatic vessels in patients with primary lymphedema
[109]. Despite that, MRI is an expensive technology and there are safety concerns re-
garding the contrast agents. The main disadvantages are low spatial resolution, application
limited to the thorax and retroperitoneum [107]. Because of these limitations, most of these
techniques are used to map out local lymphatic anatomy, but provide limited information
regarding lymphatic function.
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Meanwhile, near-infrared (NIR) imaging allows one to study lymphatic vessel function
in vivo with a non-invasive procedure using specific fluorescent dyes. NIR wavelengths
ensures low light absorption and scattering in biological tissues and provides low autoflu-
orescence, as it occurs in the optical window of tissues. Thanks to those properties, imag-
ing lymphatics using NIR-labeled lymphatic-specific tracers provides images of superficial
lymphatics with high spatial resolution and contrast [106, 110, 111]. Lymphatic specificity
of the tracers is achieved through intradermal or subcutaneous delivery of tracers in the size
range of 20 kDa up to 200 nm as these particles are too large to enter the blood vasculature
but small enough to easily convect through the interstitial matrix.
Fluorescent lymphatic imaging is used to perform lymphatic mapping and intraopera-
tive guidance. It is used to identify sentinel lymph nodes in breast and skin cancer patients
during surgery as well as in non-invasive procedures for surgical planning [112, 113, 114,
115]. This technique also allows one to evaluate lymphatic drainage pathways [116].
Another application of NIR imaging is the evaluation of the lymphatic function. For
example, one may compute the transit time of the dye from the injection site in the foot
to the knee [117]. Also, contraction of the lymphatic vessels results in the appearance of
fluorescent “packets”, in which the fluorescence propagates along the lymphatic vessels.
This has been observed in healthy patients and asymptomatic limbs of lymphedema pa-
tients, enabling one to quantify a metric of lymphatic function [106]. Several techniques
for non-invasive quantification of the lymphatic transport and pumping function have been
introduced for rodent models of lymphatic disorders [111, 118, 119, 120].
In most of the NIR imaging studies mentioned above indocyanine green (ICG) is used
as a fluorescent tracer due to the fact that it has been FDA approved for other applications
since the 1950s [106, 111, 112, 113, 114, 115, 116, 120]. When injected intradermally free
ICG binds to proteins and is taken up by the lymphatics. However, a significant fraction
of ICG was reported to also enter the blood vessels [119]. Also it was shown, that the
repetitive administration of ICG leads to the decreased lymphatic function and enlarged
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draining lymph nodes and thus may directly impair lymphatic function [118, 121].
Alternative tracers have attempted to resolve those issues: PEG conjugated NIR IRDye
and ICG liposomes have been utilized for NIR imaging [119]. Both of those tracers are
lymphatic specific and are not taken up by the blood vasculature [119] and do not inhibit
lymphatic function [118]. Liposomal ICG has the potential to target selected cells by in-
corporating antibodies or the surface ligands [122]. Further improvements to NIR based
imaging techniques and evaluation of lymphatic function will allow one to expand the clin-
ical application of this technique.
Over the years, multiple animal models have been developed to study lymphedema
and lymphatic physiology. While transgenic animals exhibit a systemic effect of the mu-
tations and high morbidity, invasive procedures result in acute swelling followed by its
spontaneous resolution and, therefore, differ from those of clinically observed secondary
lymphedema. Moreover, surgical manipulations cause localized tissue damage, making
it difficult to distinguish between wound healing and lymphatic regeneration. Therefore,
there is a need for non-invasive techniques to induce localized disruption of lymphatic ves-
sel integrity and to study to the resulting adaptations in lymphatic function to such injuries.
In this work, we sought to investigate the potential of verteporfin-based photodynamic
therapy to induce such an injury in the mouse tail. This location was chosen as it is well




EVALUATION OF LONGITUDINAL LYMPHATIC FUNCTION CHANGES
UPON INJURY IN THE MOUSE TAIL WITH PHOTODYNAMIC THERAPY
2.1 Introduction
The lymphatic system is responsible for fluid homeostasis[2], immune cell trafficking[3]
and lipid transport[1]. Protein-rich fluid from the interstitial space is transported uni-
directionally to the blood circulation in the form of lymph [4]. This liquid is collected by
initial lymphatics and transported to pre-collecting lymphatics where it is then transferred
to collecting lymphatics, which lead to lymphatic trunks or ducts and eventually return
the fluid into the blood circulation [4]. While significant strides have been made over the
past few decades understanding the molecular mechanisms important for lymphatic de-
velopment, our understanding of postnatal lymphangiogenesis in health and disease is in
its nascent stages. New animal models of lymphatic injury will thus provide useful ex-
perimental platforms for further exploring lymphatic post-natal adaptation in health and
disease.
Photodynamic therapy is widely utilized for anti-tumor treatments, age-related macular
degeneration and various dermatological conditions, such as psoriasis and vitiligo [91].
This technique is based on photosensitizer activation with non-thermal light, which leads
to generation of reactive oxygen species (ROS) [12, 95]. One of the drugs widely used for
this purpose is Visudyne R©(Novartis Ophthalmics, Hettlingen, Switzerland), a liposomal
formulation of verteporfin. This technique has been particularly effective for disrupting
newly formed vasculature, where intravenously delivered drug in concentrated in cells with
a high density of low-density lipoprotein receptors (LDLR) which assist in the endocytosis
of the drug [95]. Since the drug has been on the market for 20 years, it has been extensively
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studied with regards to its effect on blood vasculature [90, 91, 92, 95].
In recent years lymphatic-specific photodynamic therapy using verteporfin has been
explored in the context of the prevention of tumor metastasis [103]. Scientists have also
investigated lymphatic regeneration following PDT in the mouse ear [12] and investigated
the effect of PDT in combination with lymphangiogenesis inhibition on anti-tumor immu-
nity [105]. However, it is unclear how the generation of ROS during PDT alters lymphatic
function and whether this method can be used to disrupt lymphatic function in tissue beds
where the skin is thicker than the mouse ear. Lastly, while verteporfin is usually used in a li-
posomal formulation, which was designed specifically to slow its clearance from the blood
circulation, it is has not been established whether free intradermal delivery of verteporfin
may be used for lymphatic-specific PDT.
Thus the aims of this study were to (1) establish whether photodynamic therapy-induced
lymphatic injury may be developed in mice tail using non-liposomal verteporfin formula-
tion and an NIR imaging system without laser irradiation, and (2) evaluate changes in
lymphatic function following PDT using non-invasive imaging techniques.
2.2 Materials and Methods
2.2.1 Verteporfin and its activation using NIR
Verteporfin was obtained from Sigma-Aldrich (St.Louis, MO, USA). The powder was
stored protected from light at -20◦C. Since the chemical is not water-soluble, it was re-
constituted using DMSO warmed to 37◦C at a concentration of 2 mg/ml and aliquoted
for future use. To dilute the reconstituted verteporfin, 5% dextrose solution was used, as
precipitation in saline solutions may occur [123].
The drug solution was injected intradermally (ID) into the tail tip at a volume of 10 µl.
During preliminary studies dosages of 200 µg/ml, 400 µg/ml, 600µg/ml were tested out
(n=4). For these experiments, corresponding doses of DMSO in 5% dextrose solution were
used as a vehicle control to ensure that no DMSO-related effects were present. The dosage
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Figure 2.1: Absorbance spectrum of verteporfin in various solvents. Distilled water, and
5% dextrose have the same absorbance spectrum. 600 µg/ml verteporfin solution in 5%
dextrose was used for the injections. Verteporfin 2 mg/ml in DMSO represents initial stock
solution, used to create the final dilution.
of 600 µg/ml was used for the remainder of the experiments, as it caused visible changes
within the targeted area within 2 days as confirmed by NIR imaging.
In this study, a customized dual-wavelength NIR imaging system was used to both im-
age the lymphatics with a lymphatic-specific tracer and to induce photosensitizer activation
by the light. Specifically, a Cy5.5 filter set (49022-ET-Cy5.5, Chroma Technology Corp,
VT, USA) was used: excitation filter ET650/45x with a center wavelength of 650 nm and
45 nm full width at half maximum (FWHM), dichroic beam splitter T685lpxr, and emission
filter ET720/60m, where the center wavelength is 720 nm, and FWHM is 60 nm. Accord-
ing to the Visudyne R© prescription information for ophthalmological use, recommended
light dose for treating neovascular lesions is 50 J/cm2 with an administration intensity 600
mW/cm2 for 83 s [93, 123]. To determine the power delivered through the Cy5.5. filter set
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to the site of application, the power was measured at various magnifications by adjusting
the objective optical zoom and using the Thorlabs photometer PM 10-3 (Thorlabs, Newton,
NJ). As the zoom is increased, the lens distributes the available power over smaller area. As
it is presented on the Figure 2.2, measured power initially increased with increased mag-
nification as the light from the excitation source become completely contained within the
photodetector surface and then slowly decreased with increased magnification, indicating
that the some power is lost through the objective as the focus is further increased.
Figure 2.2: Power output for the Cy5.5 NIR filter at various magnifications.
We chose the maximum optical zoom of 6.3X as the light fluence was maximum here
due to the minimal illumination spot size. In addition, the size of the light beam at this
magnification allowed us to focus the beam on a specific surface of the tail of about 0.2






The power density of 275 mW/cm2 was estimated based on the laser beam area in
focus, which was a circle with approximately a 5 mm diameter (area of 0.19635 cm2).
From the equation above, an exposure time of 179 s would achieve a fluence of 50 J/cm2,
while 258 s would achieve 72 J/cm2, discussed in previous studies [103].
2.2.2 PDT in the mouse tail
Experiments were conducted on C57BL/6 mice 6-10 weeks old. Animals were separated
into two groups of 8, each comprising 4 male and 4 female mice. Animals were anes-
thetized with 5% isofluorane and kept under 1.9% isoflurane for the experiment’s dura-
tion. Mice body temperature was maintained around 37◦C. Verteporfin was resuspended
in DMSO, as described above, and prepared with 5% dextrose to achieve the desired con-
centration of 600 µg/ml and volume of 10 µl. During the first 5 minutes of injection the
tail was protected from light by covering it with aluminum foil. Then the targeted area was
irradiated with a focused beam of 0.2 cm2 to achieve verteporfin activation for 5 minutes
on the top, right and left sides at a distance 4.5 cm from the tail tip to induce lymphatic
injury on the vessels at this location. The exposure time of 5 minutes provided the fluence
of 82.5 J/cm2 at every side. This increased exposure time of 5 minutes (compared to other
published studies) was motivated by the greater tissue thickness and more absorption and
scattering of the light by the tissue of the mouse tail than in occurs in ophthalmological
applications or in mouse ear dermis. The light delivered through our filter set is also off
peak from the local absorption maximum of 700 nm, although the absorbance at 650 nm is
within 50% of this peak value.
The schematic representation of the experimental set-up is shown on Figure 2.3.
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Figure 2.3: Experimental set-up. NIR measurement of lymphatic function were made prior
to verteporfin treatment to establish baseline measurements of lymphatic function on day
0. Verteporfin was then administered intradermally in the tail tip, and the tail was exposed
to light for the activation as described in the methods (or left unexposed in control mice).
Mice received follow on measurement of lymphatic function 3, 7, 14, 21, and 28 days after
the initial injury. Figure was created with BioRender.com.
2.2.3 NIR Imaging
Lymphatic contractility function was evaluated in vivo in mice tails with NIR imaging using
previously described techniques [111, 119, 120].
20kDa polyethylene glycol (PEG) was conjugated with IRDye 800CW NHS Ester (LI-
COR Biosciences) to synthesize the lymphatic specific tracer. PEG is dissolved in DMSO
with NIR dye at a dye to PEG ratio of 1:1.5 and mixed on a shaker for 24 hours, then
transferred to dialysis cassette that has the molecular weight cut-off of 7 kDa for its semi-
permeable membrane (Slide-A-Lyzer, ThermoFisher Scientific). This cassette enables the
free diffusion of small molecules and retains the larger molecules on the sample side of
the membrane and was placed into the distilled water for 24 hours of dialysis, aliquoted
and lyophilized. The final dye is stored at -20◦C and resuspended in 0.9% saline (sodium
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chloride) for injections [124]. 10 µl of tracers is administered intradermally into the tail tip
of anesthetized mice immediately prior to imaging.
The NIR imaging system, along with MicroManager software, was used to collect the
images. The system consists of stereo-microscope MVX10 (Olympus) with an attached
electron-multiplying charge-coupled device (EMCCD) camera (Evolve eXcelon, Photo-
metrics) and xenon arc lamp light source with automated shutter controller LB-LS/30IR
(Sutter Instrument Company). The microscope is also equipped with two sets of NIR ex-
citation and emission filters, the Cy5.5 filter set described above, and a second NIR filter
set for imaging the lymphatic PEG tracer: a 769 nm bandpass excitation filter with 49nm
FWHM (Brightline FF01-769/41-25 25MM, Semrock), an 832nm nm bandpass emission
filter with 45nm FWHM (Brightline FF01-832/37-32 32MM, Semrock) and an 801.5 nm
longpass dichroic mirror (Brightline FF801-DI02-32X44-XL, Semrock) [80, 124].
The field view for the functional measurement was centered at the same location as the
site of the verteporfin activation on the mouse’s tail, 4.5 cm from the tail tip. After injection
of the tracer, the lymphatic contractile function was recorded for 5 minutes from the top
view of the mouse. Then, the left and right sides of the tail were imaged for the same
period by placing the mouse on its side. NIR exposure time on the camera was set to 50
ms with a frame rate of 10 fps. NIR functional analysis to determine the packet frequency,
packet amplitude, and packet has been described previously [80]. An ROI containing the
collecting vessel is selected and the spatially averaged intensity change over time within
the ROI is obtained and used to calculate the functional parameters.
Discrete packets of fluorescence are observed when the lymph moves through the lym-
phatic vessels due to the intrinsic contractions and operation of the lymphatic valves [120].
Packets frequency has previously been established as a measure of the lymphatic func-
tion by counting the number of contractile events [111]. The amplitude of those packets
corresponds to the contraction amplitude of the vessel [80, 125]. Here this parameter is
evaluated as a percentage difference between the maximum and baseline intensity of the
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Figure 2.4: Lymphatic function evaluation. An example packet of fluorescence is high-
lighted in the gray box. Packet frequency is the number of packets observed per minute.
Amplitude percentage difference is calculated as the difference between maximum packet
amplitude and baseline intensity divided by baseline intensity at the given timepoint. The
baseline intensity line connects the minimum intensity values of the packets. The packet
transport is calculated as the area under the curve normalized to the base line intensity,
summed over all of the packets and divided by the total time. Area under the curve is
calculated as sum differences between the intensity and baseline values for each timepoint
within the packet. In results we report the packet transport normalized to the baseline
intensity at every given point.
packet divided by the baseline signal intensity at the given time to adjust for the brightness
and averaged across the measurement time (Figure 2.4). Packet transport is calculated as an
integral of the packet frequency over time and represents the fluorescence transport driven










Where n is number of packets in the measurement, f(t) is fluorescent signal within the
packet region, limited by minimum (t1i) and maximum (t2i) time points of each packet,
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g(t) is baseline intensity within the packet.
During the follow-up measurements, if distinct collecting vessels were not visible at the
treatment area, additional data accusation was completed proximal to this area at approx-
imately 6 cm from the tail tip. All data for each animal is reported as the average of four
ROI measurements: left and right sides of the tail with two vessels within each location.
2.2.4 Quantification of lymphatic leakage
To evaluate the amount of dye that had leaked out at the injury site, image processing
techniques were applied. The first step was the identification of the mouse tail. Percentile
based filtering was proven to be the most effective for this task.
The distribution of intensities within the image is used for this evaluation. The function
identifies the intensity at which 72% of the pixels in the image have lower fluorescence than
the top 28%. These pixels are set to a zero value, while the other 28% remain unchanged.
This percentile was selected based on the assumption that the tail occupies a relatively
consistent area of the image in a given video sequence. This final value was selected
through multiple runs across a random selection of mice.
Segmentation of the dye within the tail was based on the calculating the mean intensity
within the tail and selecting 20% of the brightest pixels above the mean.
The code was developed by using Python, including optimized libraries, such as NumPy
and SciPy. Therefore, this code can be executed on various operating systems as an open-
source tool and is included in the appendix.
2.2.5 Statistical analysis
To evaluate the effects of time since injury, and the effect of light activation of verteporfin,
non-parametric paired and unpaired tests were performed to determine the statistical sig-
nificance of the results. Mann-Whitney test was used to compare difference between two
animal groups, while Wilcoxon test identified significant changes from the baseline mea-
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surements. Two-way ANOVA was applied to evaluate lymphatic function change on day 7
in animals of different gender. Tuckey’s multiple comparison test was performed following
ordinary one-way ANOVA to evaluate the effect of verteporfin based treatment downstream
from the injury location. A Shapiro-Wilk test was performed to test for normality, and while
most of the data for the groups was normally distributed, there were some exceptions likely
due to the small sample size. All statistical computations were performed using GraphPad
Prism 8.4.3.
2.3 Results
2.3.1 Automated tail and dye detection
Examples of the tail and dye detection algorithm are represented on Figures 2.5 and 2.6.
Unlike surgical injury of the mouse tail lymphatics, there was no detectable tail swelling
in these animals (Figure 2.7 A). In animals with the low overall fluorescence levels, the
tail thresholding included some pixels as positive that can clearly be seen to be in the
background upon visual inspection. However, this small amount of noise did not influence
the estimation of the tail size and was not observed for the animals with higher fluorescence
intensity within the tail.
Under normal conditions, the tracer is taken up by initial lymphatics at the injection site
and transported downstream within collecting lymphatics such that only collecting lym-
phatics are visible at the imaging site (Figure 2.5, Figure 2.6 A,B). Control mice presented
with clear anatomically distinct collecting lymphatic vessels during all of the follow-up
days. PDT treated mice exhibited leakage of tracer out of the collecting vessels and of-
ten showed uptake into the surrounding hexagonal initial lymphatic network. When these
images were quantified, there were no significant differences between the baseline and
the follow-on days in the measurement of dye distribution in verteporfin-only animals.
In PDT treated mice, such changes were observed. Specifically, the fluorescent tail area
percentage significantly increased on day 7 18.322±9.597, day 14 18.999±11.156, day 21
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18.204±16.563 and day 28 14.910±10.789 post procedure in comparison with the baseline
measurement 7.315±2.725 (mean±SD) (Figure 2.7 B).
Figure 2.5: Example of tail and dye detection in verteporfin only group (control group).
Top row represents the baseline day 0 measurements, bottom row represents day 3 follow-
up. (A,C) Results of the tail detection algorithm, (B,D) fluorescent area.
Figure 2.6: Example of tail and dye detection in verteporfin with light activation group
(PDT group). Top row represents the baseline day 0 measurements, bottom row represents
day 3 follow-up. (A,C) Results of the tail detection algorithm, (B,D) fluorescent area.
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Figure 2.7: Lymphatic PDT result in increased dye leakage from lymphatics at the site of
injury. (A) Image area occupied by the tail was evaluated as a detected number of pixels
over the total number of pixels in the image. There were no detectable changes in tail size
between either group over the 28 day period. (B) PDT treated animals developed an in-
crease in the tail area with fluorescence tracer above background, indicating dye leakage
at the site of injury, while statistical differences were also observed in the control group
(verteporfin only) on day 7 in comparison with baseline measurement. (C) There were
significant differences in brightness at the imaging site in comparison with the baseline
measurement, where the intensity was consistently higher for the PDT group. No statis-
tically significant differences were observed between control and PDT groups, suggesting
that while enhanced leakage was occurring, the lymphatic tissue bed was still capable of
clearing the dye. Significance on this graph is shown for the comparison of each day to the
baseline measurement within the study groups using Wilcoxon test. *represents a statisti-
cally significant difference determined by Mann-Whitney test: comparison between animal
groups at the given time point. # represents a statistically significant difference determined
by Wilcoxon test: comparison with the baseline measurement of the same animal group.
#P<0.05, n=8 for both animal groups. Error bars represent mean±SE
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Tail and fluorescence area detection was completed using automated image processing.
Since every measurement contained a few thousand images, their averages were used to
report the results. From this, the data for each side of the tail was obtained (Figure C.1).
Considering that observed trends were similar between the sides, right, left, and top side
measurements were averaged for every animal (Figure 2.7).
2.3.2 Lymphatic function changes following the PDT
Several measures of lymphatic function parameters were significantly decreased after PDT
treatment (Figure 2.8). Particularly, a statistically significant difference in normalized
packet frequency between PDT 0.334±0.625 and control 1.333±0.448 groups was ob-
served on day 7. This parameter also significantly decreased in comparison to the base-
line values in PDT group on day 3 0.353±0.616 and day 7 (Figure 2.8 A). Normalized
packet transport, which is a measure of the fractional pump flow due to contraction, for
PDT mice significantly changed on day three 0.328±0.466, day 14 0.2±0.248 and day
28 0.396±0.524 in comparison with the baseline, while for control mice such change
occurred only on day 28 0.542±0.265. Statistically significant difference between PDT
0.200±0.248 and control 0.646±0.455 animal groups was present on day 14 (Figure 2.8
B). Packet amplitude, which is indicative of contraction amplitude of the vessel wall, was
statistically different from the baseline measurement for PDT treated animals on day 3
0.254±0.36, day 7 0.393±0.683, day 14 0.195±0.318, and day 28 0.348±0.435; for con-
trol animals on day 28 only 0.667±0.346. Normalized packet amplitude was also signif-
icantly different between PDT and control groups on day 3 and day 14, when the values
for control group were 0.903±0.885 and 0.747±0.398,respectively (Figure 2.8 C). All the
values above represent mean±SD.
As a general trend, after day 14, lymphatic function in PDT treated animals returns
close to the baseline levels after a transient loss of function early on. At the same time, the
function in control mice remains consistent throughout the experiment.
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Figure 2.8: Lymphatic function decreased over time in PDT animal group. Parameters of
lymphatic function throughout the study. (A) Packet frequency for PDT was less than con-
trol one week following the procedure, while no statistically significant differences were
present between PDT and control in following weeks. (B) Normalized packet transport sig-
nificantly decreased from baseline values on days 3, 14, and 28 for the PDT group while for
the control group there was a statistically significant decrease in packet transport at day 28.
Between two groups statistically significant difference was observed on day 14. (C) Packet
amplitude was significantly lower in PDT group on days 3, 7, 14, and 28 post-treatment
while in control group statistically significant differences in packet amplitude was observed
on day 28. Control and PDT group presented statistically significant differences on days
3 and 14. *represents a statistically significant difference determined by Mann-Whitney
test: comparison between animal groups at the given time point.# represents a statistically
significant difference determined by Wilcoxon test: comparison with the baseline measure-
ment of the same animal group. *P<0.05, **P<0.01, #P<0.05 ##P<0.01, n=8 for control
group, n=7 for PDT group. Error bars represent mean±SE.
As significant differences between the two animal groups were observed on day 7, we
used this day to complete further comparison between genders and to study the lymphatic
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function proximal and downstream to the injury site.
2.3.3 No gender differences in function as injury response
Figure 2.9: Verteporfin treatment outcomes are independent of animal gender. Lymphatic
function evaluated on day 7 presents difference between verteporfin only and light activated
animal groups. *P<0.05, **P<0.01, n=8 for control group, n=7 for PDT group. Error bars
represent mean±SE.
Given the increase prevalence of lymphedema in women compared to men, we sought
to determine if there were gender differences in the response to injury. Both male and fe-
male mice were used in the study and the effect of gender on the results was investigated on
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day 7, when significant changes due to PDT therapy were observed. Photodynamic therapy
treatment provided an equal effect on both male and female mice, with PDT decreasing
lymphatic function across all measures at this timepoint (Figure 2.9).
2.3.4 PDT alters lymphatic function in downstream lymphatics proximal to the injury site
To determine if the loss of lymphatic function occurred only at the exact site of light activa-
tion, or if its effects could be propagated to lymphatics downstream, we imaged lymphatic
7 days after surgery 6 cm from the tail tip (Figure 2.10). Downstream of the injury there
were significant reductions in function compared to the control group for most functional
parameters, however, there was no difference for packet frequency. There was also no
difference in function between the site of light activation and the site further downstream.
Specifically, packet frequency [packets/min] was significantly lower for the PDT animal
group at the injury site 0.934±1.582 in comparison with verteporfin only 4.523±1.538
(Figure 2.10 A). Packet transport [IU] was significantly decreased for the animals with
verteporfin activation at the site of the light application 3.443±4.807 and proximal from
it 4.316±7.072 in contrast to the verteporfin without light activation group 13.146±5.133
(Figure 2.10 B). The same trend was observed for the average packet amplitude percentage
difference, where amplitude for verteporfin only 0.048±0.018 was significantly greater
than for PDT injury site 0.009±0.012 or PDT at 6 cm from the tail tip 0.016±0.022 (Figure
2.10 C). Values above represent mean±SD. Number of animals in the verteporfin treatment
(PDT) downstream was 5 as oppose to 7 animals in PDT group and 8 animals in control
group.
As a result, it was shown that photodynamic therapy can be administered and longitu-
dinal function imaged using a dual-wavelength NIR stereomicroscope system and intrader-
mal delivery of non-liposomal verteporfin. This treatment resulted in increased lymphatic
permeability and loss of lymphatic contractile function, which peaked one week after injury
and resolved within one month.
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Figure 2.10: Decreased lymphatic function was observed downstream from the injury site.
Function in PDT animals was evaluated at the injury site (4.5 cm from the tail tip) and
proximal to it (6 cm from the tail tip). One-way ANOVA and Tuckey’s multiple compar-
isons test *P<0.05, **P<0.01, n=8 for control group, n=7 for PDT group, n=6 for PDT
downstream measurement. Error bars represent mean±SE.
2.4 Discussion
When delivered intradermally at the tip of the mouse tail, we hypothesized that verteporfin
would still be taken up primarily in lymphatics, similar to other hydrophobic small molecules
such as has been shown with indocyanine green, due to the rapid bind to interstitial pro-
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teins and clearance by lymphatics. It has been suggested that as a protein-bound drug,
verteporfin in non-liposomal formulation can be taken up by endothelial cells by binding to
LDL and entering the cells through the LDL receptor [95] and given that lymphatics drain
lipoproteins from the tissue space [127], such a mechanism would also be possible for lym-
phatics. Although complete lymphatic ablation did not occur, we observed similar results
to that seen in lymphatics in the ear skin when the lower light fluence was used to activate
a liposomal formulation of the drug [12]. We took advantage of this initial mild disrup-
tion in lymphatic permeability is response to PDT, to investigate the longitudinal effects of
treatment and the consequence to lymphatic contractile function.
For half of the injury group, the function was restored by day 28, while the other half
still did not present any pumping. Most importantly, considerable changes following the
verteporfin administration and its activation were observed 72 hours after the treatment.
Upstream and downstream from the treatment site, the lymphatics appeared visually normal
for most of the animals, while the packet amplitude and packet transport were significantly
decreased (Figure 2.9).
The most apparent change following photodynamic therapy was the change in the tail
fluorescence and NIR tracer distribution. Therefore, an additional metric was introduced
to estimate the fluorescent area and mean fluorescence of the tail. The mean brightness
increases with the dye accumulation indicating lymphatic transport stasis. The fluorescent
area represents the dye distribution within the tail. In control animals, it did not signifi-
cantly change as the NIR tracer was distributed only within the collecting lymphatic ves-
sels and limited initial lymphatics. However, in animals after the photodynamic therapy,
the dye was observed to leak into the interstitium, increasing the fluorescent area of the
tail occupied by tracer, and suggesting enhanced permeability due to the localized action
of ROS as a result of PDT treatment. A similar pattern was presented for the normalized
mean fluorescence.
Initial lymphatics were observed throughout the study in multiple animals. Therefore,
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we decided to investigate if the amount of hexagonal-shaped initial lymphatics will change
following the verteporfin administration and its activation. Two animals, one per each study
group, were excluded as they presented a hexagonal network during the baseline measure-
ments. As a result, the increase in the number of initial lymphatics was observed for every
animal from the PDT group, starting on day 3. The number of visible initial lymphatics
was decreasing, in cases where lymphatic leakage was reduced. However, those vessels re-
mained prominent in animals with a high amount of interstitial fluid. In the control group,
such a radical increase in the count of initial lymphatics was not observed. However, if
they were visualized, it was at least a week after the verteporfin administration. Since ini-
tial lymphatics were taking up the NIR tracer accumulated in the interstitium following the
PDT, we conclude that initial lymphatics were recruited to transport the lymph when the
integrity of collecting lymphatics was compromised.
In the single vessel ligation animal model correlation between the tail swelling and
lymphatic dysfunction was reported. Lymphatic dysfunction was characterized by packet
transport [80]. In this study, tail swelling did not occur and the leaky lymphatics that were
observed did not lead to the increased tail circumference (Figure 2.7 A). From this, we infer
that the swelling is not required for the loss of lymphatic pumping function, and in PDT
injury of lymphatic vessels those two results are not conjugated as in the surgical model of
lymphedema.
As it was mentioned before, the packet frequency and packet transport declined follow-
ing PDT (Figure 2.8, 2.9, 2.10). Simultaneously, the amount of interstitial fluid at the injury
site was increased due to leakage of lymph at the site of injury. Previous studies revealed
that an increased volume of dye injection leads to decreased contractility of the lymphatic
vessels, even though the volumetric flow rate in the vessel is elevated [128], thus impaired
contractility is not necessarily indicative of reduced lymphatic flow. On the contrary, it has
been known for some time that elevated flow though lymphatic vessels can trigger a wall
shear stress mediated inhibition of lymphatic contraction [129, 130, 131, 132, 133]. Based
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on these reports, even though the lymphatic contractile frequency was reduced after PDT,
the lack of swelling suggests that the transport of the lymph still occurs, and the leakiness
is compensated for by a sufficient volume flow rate driven by interstitial fluid pressure.
In previous surgically induced injury models there was a delayed reduction in lymphatic
transport in the intact vessel following the single vessel ligation model [80]. Similarly to
that, the lymphatic contractile function was decreased or absent proximal to the photody-
namic injury location (Figure 2.10), and loss of contraction function was delayed. Consid-
ering that inflammatory cytokines decrease collecting lymphatic pumping [134, 135], the
reduced function of the lymphatics along the tail that was observed could be consequence
of an inflammatory response to PDT [80].
As it has been reported before, lymphatic and blood vessels permeability can be in-
creased as a result of photodynamic therapy [12, 95]. The efficacy of photodynamic therapy
is influenced by multiple factors, such as the target area, light power, drug dosage and dura-
tion of light administration [95]. In this study, an NIR Cy5.5 filter was used for verteporfin
activation, which does not target the verteporfin absorption peak that occurs between 690-
695 nm (Figure 2.1). Therefore, the administered light dosage was increased by extending
the exposure time. Achieved results (Figure 2.5, 2.6) are similar to the previously observed
lymphatic hyperpermeability seen under low-dose liposomal verteporfin treatment [12].
One advantage to our approach was that the secondary NIR channel, in combination with
injection of NIR tracers, allowed us to focus the beam directly at the depth of the collecting
lymphatic vessel prior to switching over to the activation wavelength. Since the exposure
area was limited through the optical set-up, this allowed up to achieve verteporfin activation
exclusively in the targeted area.
Increased lymphatic permeability observed in this study correspond to the previously
described effects of verteporfin. One important thing to note, is that verteporfin itself is a
Yes associate protein (YAP) inhibitor [136, 137] and has been shown to suppress expression
of Ang2, VE-cadherin, MMP2 and α-SMA [138], which facilitate angio-and lymphangio-
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genesis and form the cell-cell junction between the LECs [28, 31, 139]. The YAP/TAZ
pathway has also been shown to be a negative regulator of Prox1, and that inhibiting it
had beneficial effects in attenuating pathological lymphangiogenesis in an inflammation
model in the cornea [140]. While we cannot discount that treatment with verteporfin alone
might have some baseline effect on lymphatic function and permeability, our data demon-
strate that light activation is necessary to produce the observed changes, suggesting the
mechanism of action is through the production of free oxygen radicals rather than through
inhibition of YAP.
Photodynamic therapy could be utilized to study the effect of increased lymphatic per-
meability in healthy and pathophysiological states. Changes in lymphatic permeability
have previously been associated with various conditions such as obesity, adipose tissue for-
mation, and fibrosis. A suggested verteporfin application regiment provides a framework
to increase lymphatic permeability and generate localized reactive oxygen species. Since
the mouse tail is often used to study lymphedema, such PDT may provide an additional
improvement to the single vessel ligation model as a preconditioning treatment, which may
prolong the surgery effect. Additionally, such an injury would allow us to study the local
impact of lymphatic leakiness on the resolution of lymphedema.
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CHAPTER 3
CONCLUSION AND FUTURE WORK
The goal of this thesis was to evaluate the application of lymphatic-specific photodynamic
therapy to establish an experimental model of lymphatic injury. This was accomplished in
a mouse tail model through the implementation of commercially available non-liposomal
verteporfin and an NIR imaging system. The same NIR setup was used to access lymphatic
function with a different filter set. The mouse tail was chosen as a target location, thanks
to previously established lymphedema models and provided a framework to evaluate con-
tractile function. Additional analysis was introduced to evaluate the fluorescent area of the
tail and the brightness values. For that purpose, the same images, collected as a functional
measurement, were used. Considering that every single measurement out of 288 contains
around 3000 images, automated processing was used. The main advantages are automated
tail detection within the image, even in case of the low brightness and dye detection without
overestimation, which was observed for adaptive thresholding.
As a consequence of the selected drug and light stimulation, consistent results were
obtained. While the control group did not present significant changes from the baseline
measurements, animals with light-activated drug showed increased permeability at the site
of light exposure. Functional analysis reflected the observed changes. In the photodynamic
therapy group, there were multiple days when no function was observed. In several ani-
mals, it was not restored by day 28 post-PDT, and downstream lymphatics were not visible.
For this group of animals, we can conclude that partial lymphatic ablation occurred in addi-
tion to modified permeability. Therefore, the most consistent result was hyperpermeability.
It was identified as NIR tracer leakage from the lymphatic vasculature into the interstitium.
The maximum increase in the leakage was measured at one and two weeks following the
treatment.
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Based on these results, the following improvements could be implemented in future
studies. The wavelength of the Cy5.5 filter was able to deliver the photodynamic therapy.
In future work, the use of a light source with the wavelength matching the absorbance peak
of the verteporfin at higher power density would decrease the amount of administered drug
and exposure time needed, which is defined by the power density and desired energy. Such
a solution could be provided, for example, by a Cy7 filter for NIR system with central wave-
length 710 and FWHM 75. Further histology of tail samples will provide additional insight
into biological contributions to the observed changes and the mechanism responsible for
lymphatic regeneration.
This study has shown that the PDT with verteporfin can be activated in the mouse tail
to alter lymphatic permeability. Another potential utilization of such findings would be a
combination of PDT with a single vessel ligation model of lymphedema. Since spontaneous
swelling resolution can confound results in the current animal model, preconditioning ani-
mals with the PDT before the single vessel ligation surgery may prolong the swelling and
provide a framework for investigating the role of hyperpermeability in lymphatic pathology
and its resolution.
Considering that reactive oxygen species are an integral part of the verteporfin activa-
tion and have a negative impact on lymphatic contractions [141], this model could be used
to study oxidative stress and test the tools to suppress it. As ROS are short-lived molecules,
the administration of antioxidants should be performed immediately after the PDT is con-
ducted or as a prior treatment. Overall, the established methodology is useful in examining
the ROS effect on the local tissues, lymphatic adaptation to increased permeability, and
the influence of enhanced lymphatic permeability on the lymphedema progression. This
framework may facilitate research focused on lymphatic regeneration, restoration of the
pumping function, and mitigation of negative consequences of reactive oxygen species.
The described photodynamic therapy regiment was effective in vivo and could be poten-
tially applied to isolated vessels following corresponding adjustment of the administered
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drug dose and exposure time.
While leaky lymphatics are observed in transgenic mouse models of lymphedema, this
parameter is not extensively studied as an initial condition in various surgical models of
the pathology [55, 142]. Photodynamic therapy provides a tool to induce changes without
the use of transgenic animals and allows one to induce those changes locally with a high
degree of regional specificity. This could create a predisposition to low-grade inflammation
with dilated and leaky lymphatics [142].
In this experiment, the photodynamic therapy was a one-time procedure administered
at the single site on the tail. This leads to significant changes in lymphatic contractile func-
tion both at the site of the light activation and proximal from it. Further investigation of
lymphatic regeneration following such injury may involve repetitive PDT at the same loca-
tion. In this case, if these procedures will be separated by sufficient time, this may prolong
the obtained effect and delay lymphatic regeneration. However, it is also possible that in
case of frequent administration or increased power, the procedure will lead to complete
ablation of the lymphatics and lymph stasis. On the one hand, the light activation area
could be expanded, and the lymphatic leakage can be induced along the whole tail to study
lymphatic function and immune response to such changes in the local environment. On
the other hand, reducing the treatment area to only one vessel may provide another tool to
study the lymphatic adaptation and local modifications, similar to the single vessel ligation
model [80] without interruption of the skin integrity.
The presented methodology describes an easily administered, non-invasive, and fast-
acting procedure to induce the targeted injury of the lymphatic vessels and modify their
local environment. Utilization of the existing NIR set-up allows for the continuous eval-
uation of the lymphatic function adaptation to the administered verteporfin-based therapy.
This PDT technique may be used as an independent animal model of lymphatic hyperper-
meability and ROS-affected lymphatics as well as an additional tool to improve existing



































































DETAILED RESULTS FOR FUNCTIONAL ANALYSIS
45
Figure B.1: Lymphatic function evaluation from left and right side of the tail at the injury
site at the 4.5 cm from the tail tip.
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APPENDIX C
DETAILED RESULTS FROM TAIL DETECTION ALGORITHM
47



























































































































































































































































































































































































































































5 import numpy as np
6 from scipy import stats






13 self.processing_option = 1
14 self.input_dir = os.getcwd()




19 stats = dict()
20 stats[’tail_area’] = []
21 stats[’bright_area’] = []
22 stats[’max_value’] = []
23 stats[’min_value’] = []
24 stats[’mean_value’] = []




29 # Checking the folder and based on that #




34 print(f’Generating output directory {folder}_output’)
35 self.input_dir = os.path.join(os.getcwd(),folder)
36 self.output_dir = os.path.join(os.getcwd(),folder + ’_output
’)
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50 # Initial check of the files in the main folder
51 stats = self.prepare_stats_container()





55 # retrieving all the files from the folder and all its
subfolders
56 for root, dirs, files in os.walk(self.input_dir):
57 for folder in dirs:
58 input_dir = os.path.join(root,folder)
59
60 # created to output folder
61 output_dir = os.path.join(self.output_dir,root[len(self.input_dir)
+1:],folder)
62 stats = self.prepare_stats_container()
63 if not os.path.exists(output_dir):
64 os.mkdir(output_dir)
65
66 # performs analysis for the folder
67 stats = self.go_through_files(input_dir,output_dir,
stats)
68
69 # generates the files with the results
70 self.output_stats(output_dir, stats)
71
72 def go_through_files(self, input_dir, output_dir, stats):
73 files_to_process = glob.glob(input_dir + ’\*.tif’, recursive=
True)
74 print(f’Processing: {input_dir}’)
75 count = 0
76 for path in files_to_process:
77 try:
78 data = imageio.imread(path).astype(’uint16’)
79 except (ValueError,PermissionError):
80 print(f’non accessible file. Skipping {path}’)
81 continue
82
83 stats, whole_tail, local_image = self.process_image(data,
stats)
84 count = count + 1
85 if count % 500 == 0:








92 def normalize_data(self, data):




96 # Image processing #
97 ##################################################
98 def process_image(self, image, stats):
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99 # normalizeing the image
100 local_image = np.copy(image/256)
101 local_image = self.normalize_data(local_image)
102 local_image = (local_image).astype(np.uint8)
103
104 threshold = np.quantile(local_image,0.72)
105 whole_tail = np.copy(local_image)
106 whole_tail[whole_tail < threshold] = 0
107
108 stats[’tail_area’].append(np.count_nonzero(whole_tail > 0))
109 stats[’max_value’].append(np.max(image[whole_tail > 0]))
110 stats[’min_value’].append(np.min(image[whole_tail > 0]))
111 stats[’median_value’].append(np.median(image[whole_tail > 0]))
112 stats[’mean_value’].append(np.mean(image[whole_tail > 0]))
113
114
115 # extracting the brightest spots
116 if self.processing_option == 1:
117 threshold = np.quantile(local_image,0.90)
118 local_image[local_image < threshold] = 0
119
120 for i in range(0,512):
121 column = local_image[:,i]
122 threshold = np.quantile(column,0.93)




127 mean_value = np.mean(whole_tail[whole_tail > 0])
128 percentage = 0.8
129 threshold = np.max(local_image[whole_tail > 0]) -
130 (np.max(local_image[whole_tail > 0])
131 - mean_value) * percentage
132 #print(mean_value,threshold,np.max(local_image[whole_tail >
0]))
133 local_image[local_image < threshold] = 0
134 stats[’bright_area’].append(np.count_nonzero(local_image > 0))
135 return stats, whole_tail, local_image
136
137 def output_stats(self, output_dir, stats):
138 if len(stats[’tail_area’]) > 0:
139
140 plt.figure()
141 plt.plot(stats[’tail_area’], marker=’o’, drawstyle="steps-post")






148 plt.plot(stats[’mean_value’], marker=’o’, drawstyle="steps-post"
)















162 plt.plot(stats[’bright_area’], marker=’o’, drawstyle="steps-post
")






169 plt.plot(stats[’max_value’], marker=’o’, drawstyle="steps-post")






176 plt.plot(stats[’min_value’], marker=’o’, drawstyle="steps-post")






183 plt.plot(stats[’median_value’], marker=’o’, drawstyle="steps-
post")















198 with open(os.path.join(output_dir,’data.csv’),’w’) as f:
199 f.write(’tail area,bright area,max value,min value,median
value,mean value\n’)
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208 extract = mice_experiment()
209 found_folder = False
210
211 while not found_folder:
212 folder_name = input(’Folder to be analyzed: ’)
213 found_folder = extract.init_output_structure(folder_name)
214
215 which_filter = input(’Do you want to use mean filtering? [y/n]’)
216
217 if which_filter == ’y’ or which_filter == ’Y’:
218 extract.processing_option = 2
219
220 # start going through files
221 extract.perform_analysis()
222








3 import pandas as pd
4 import numpy as np






11 self.name = folder[folder.rfind(os.path.sep)+1:folder.rfind(
’_’)]
12 print(f’Found directory {folder},\nGenenerating output file
{self.name}.csv’)




17 print(’This directory does not exist)’)
18 return False
19
20 def prepare_container(self, keys):
21 stats = dict()
22 stats[’folder name’] = []
23 for key in keys:
24 stats[key] = []
25 stats[key + " error"] = []
26 stats[key + " var"] = []






33 name = csv_file.lower()
34
35 if name.find(’pos0’) != -1:
36 name = name[0:name.find(’pos0’)-1]
37 return name[name.rfind(os.path.sep)+1:].upper()
38




43 files_to_process = glob.glob(self.input_dir + os.path.sep +’**’+
os.path.sep + ’*.csv’, recursive=True)
44 if len(files_to_process):
45 # read the first found csv to gather the keys used
46 data = pd.read_csv(files_to_process[0])
47 output_container = self.prepare_container(data.keys())
48
49 for csv_file in files_to_process:
50 data = pd.read_csv(csv_file)




54 for key in data.keys():
55 output_container[key].append(np.mean(data[key]))
56 output_container[key + " error"].append(stats.sem(
data[key]))
57 output_container[key + " var"].append(np.var(data[
key]))









65 data = pd.DataFrame.from_dict(stats)




69 extract = csv_analysis()
70 found_folder = False
71
72 while not found_folder:
73 folder_name = input(’Folder to be analyzed: ’)
74 found_folder = extract.search_for_folder(folder_name)
75 extract.search_csv()
76
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rolainen, I. Immonen, and K. Alitalo, “Photodynamic ablation of lymphatic ves-
sels and intralymphatic cancer cells prevents metastasis”, Science Translational
Medicine, vol. 3, no. 69, pp. 1–8, 2011.
[104] W. W. Kilarski, “Physiological Perspective on Therapies of Lymphatic Vessels”,
Advances in Wound Care, vol. 7, no. 7, pp. 189–208, 2018.
[105] A. Muchowicz, M. Wachowska, J. Stachura, K. Tonecka, M. Gabrysiak, D. Wołosz,
Z. Pilch, W. W. Kilarski, L. Boon, T. J. Klaus, and J. Golab, “Inhibition of lymphan-
giogenesis impairs antitumour effects of photodynamic therapy and checkpoint in-
hibitors in mice”, European Journal of Cancer, vol. 83, pp. 19–27, 2017.
[106] J. C. Rasmussen, I. C. Tan, M. V. Marshall, C. E. Fife, and E. M. Sevick-Muraca,
“Lymphatic imaging in humans with near-infrared fluorescence”, Current Opinion
in Biotechnology, vol. 20, no. 1, pp. 74–82, 2009.
77
[107] S. Yousefi, Zhongwei Zhi, and R. K. Wang, “Label-Free Optical Imaging of Lym-
phatic Vessels Within Tissue Beds IN VIVO”, IEEE Journal of Selected Topics in
Quantum Electronics, vol. 20, no. 2, pp. 15–24, 2014.
[108] “MRI of the Central Lymphatic System”, Topics in Magnetic Resonance Imaging,
vol. 26, no. 4, pp. 175–180, 2017.
[109] “Role of contrast enhanced MRI lymphangiography in evaluation of lower extrem-
ity lymphatic vessels for patients with primary lymphedema”, Egyptian Journal of
Radiology and Nuclear Medicine, vol. 49, no. 3, pp. 776–781, 2018.
[110] J. Rao, A. Dragulescu-Andrasi, and H. Yao, “Fluorescence imaging in vivo: recent
advances”, Current Opinion in Biotechnology, vol. 18, no. 1, pp. 17–25, 2007.
[111] M. Weiler, T. Kassis, and J. B. Dixon, “Sensitivity analysis of near-infrared func-
tional lymphatic imaging”, Journal of Biomedical Optics, vol. 17, no. 6, p. 066 019,
2012.
[112] T. Kitai, T. Inomoto, M. Miwa, and T. Shikayama, “Fluorescence navigation with
indocyanine green for detecting sentinel lymph nodes in breast cancer”, Breast
Cancer, vol. 12, no. 3, pp. 211–215, 2005.
[113] M. Fujiwara, T. Mizukami, A. Suzuki, and H. Fukamizu, “Sentinel lymph node
detection in skin cancer patients using real-time fluorescence navigation with in-
docyanine green: preliminary experience”, Journal of Plastic, Reconstructive &
Aesthetic Surgery, vol. 62, no. 10, e373–e378, 2009.
[114] N. Tagaya, R. Yamazaki, A. Nakagawa, A. Abe, K. Hamada, K. Kubota, and T.
Oyama, “Intraoperative identification of sentinel lymph nodes by near-infrared flu-
orescence imaging in patients with breast cancer”, The American Journal of Surgery,
vol. 195, no. 6, pp. 850–853, 2008.
[115] E. M. Sevick-Muraca, R. Sharma, J. C. Rasmussen, M. V. Marshall, J. A. Wendt,
H. Q. Pham, E. Bonefas, J. P. Houston, L. Sampath, K. E. Adams, D. K. Blanchard,
R. E. Fisher, S. B. Chiang, R. Elledge, and M. E. Mawad, “Imaging of lymph
flow in breast cancer patients after microdose administration of a near-infrared flu-
orophore: Feasibility study”, Radiology, vol. 246, no. 3, pp. 734–741, 2008.
[116] Y. Ogasawara, H. Ikeda, M. Takahashi, K. Kawasaki, and H. Doihara, “Evaluation
of Breast Lymphatic Pathways with Indocyanine Green Fluorescence Imaging in
Patients with Breast Cancer”, World Journal of Surgery, vol. 32, no. 9, pp. 1924–
1929, 2008.
[117] N. Unno, M. Nishiyama, M. Suzuki, N. Yamamoto, K. Inuzuka, D. Sagara, H.
Tanaka, and H. Konno, “Quantitative Lymph Imaging for Assessment of Lymph
78
Function using Indocyanine Green Fluorescence Lymphography”, European Jour-
nal of Vascular and Endovascular Surgery, vol. 36, no. 2, pp. 230–236, 2008.
[118] M. Weiler and J. B. Dixon, “Differential transport function of lymphatic vessels in
the rat tail model and the long-term effects of Indocyanine Green as assessed with
near-infrared imaging”, Frontiers in Physiology, vol. 4, no. August, pp. 1–10, 2013.
[119] S. T. Proulx, P. Luciani, A. Christiansen, S. Karaman, K. S. Blum, M. Rinderknecht,
J.-C. Leroux, and M. Detmar, “Use of a PEG-conjugated bright near-infrared dye
for functional imaging of rerouting of tumor lymphatic drainage after sentinel
lymph node metastasis”, Biomaterials, vol. 34, no. 21, pp. 5128–5137, 2013.
[120] T. S. Nelson, R. E. Akin, M. J. Weiler, T. Kassis, J. A. Kornuta, and J. B. Dixon,
“Minimally invasive method for determining the effective lymphatic pumping pres-
sure in rats using near-infrared imaging”, American Journal of Physiology-Regulatory,
Integrative and Comparative Physiology, vol. 306, no. 5, R281–R290, 2014.
[121] A. A. Gashev, T. Nagai, and E. A. Bridenbaugh, “Indocyanine Green and Lym-
phatic Imaging: Current Problems”, Lymphatic Research and Biology, vol. 8, no. 2,
pp. 127–130, 2010.
[122] J. C. Kraft and R. J. Y. Ho, “Interactions of Indocyanine Green and Lipid in Enhanc-
ing Near-Infrared Fluorescence Properties: The Basis for Near-Infrared Imaging in
Vivo”, Biochemistry, vol. 53, no. 8, pp. 1275–1283, 2014.
[123] Novartis Ophthalmics, Visudyne (verteporfin for injection). Professional Product
Labeling. NDA 21-119/S-001. 2001.
[124] “Endothelin-1 inhibits size dependent lymphatic clearance of PEG-based conju-
gates after intra-articular injection into the rat knee”, Acta Biomaterialia, vol. 93,
pp. 270–281, 2019.
[125] C. Chong, F. Scholkmann, S. B. Bachmann, P. Luciani, J.-C. Leroux, M. Detmar,
and S. T. Proulx, “In vivo visualization and quantification of collecting lymphatic
vessel contractility using near-infrared imaging”, Scientific Reports, vol. 6, no. 1,
p. 22 930, 2016.
[126] T. S. Nelson, “The functional and remodeling response of collecting lymphatic ves-
sels to disruption of lymphatic drainage pathways”, PhD thesis, Georgia Institute
of Technology, 2018.
[127] H. Y. Lim, C. H. Thiam, K. P. Yeo, R. Bisoendial, C. S. Hii, K. C. McGrath, K. W.
Tan, A. Heather, J. S. J. Alexander, and V. Angeli, “Lymphatic Vessels Are Es-
sential for the Removal of Cholesterol from Peripheral Tissues by SR-BI-Mediated
Transport of HDL”, Cell Metabolism, vol. 17, no. 5, pp. 671–684, 2013.
79
[128] E. M. Bouta, C. Blatter, T. A. Ruggieri, E. F. Meijer, L. L. Munn, B. J. Vakoc,
and T. P. Padera, “Lymphatic function measurements influenced by contrast agent
volume and body position”, JCI Insight, vol. 3, no. 2, 2018.
[129] A. A. Gashev, “Inhibition of the active lymph pump by flow in rat mesenteric lym-
phatics and thoracic duct”, The Journal of Physiology, vol. 540, no. 3, pp. 1023–
1037, 2002.
[130] A. A. GASHEV, “Physiologic aspects of lymphatic contractile function”, Annals
of the New York Academy of Sciences, vol. 979, no. 1, pp. 178–187,
[131] A. Koller, R. Mizuno, and G. Kaley, “Flow reduces the amplitude and increases
the frequency of lymphatic vasomotion: Role of endothelial prostanoids”, Ameri-
can Journal of Physiology - Regulatory Integrative and Comparative Physiology,
vol. 277, no. 6 46-6, pp. 1683–1689, 1999.
[132] J. A. Kornuta, Z. Nepiyushchikh, O. Y. Gasheva, A. Mukherjee, D. C. Zawieja, and
J. B. Dixon, “Effects of dynamic shear and transmural pressure on wall shear stress
sensitivity in collecting lymphatic vessels”, American Journal of Physiology - Reg-
ulatory Integrative and Comparative Physiology, vol. 309, no. 9, R1122–R1134,
2015.
[133] A. Mukherjee, J. Hooks, Z. Nepiyushchikh, and J. B. Dixon, “Entrainment of Lym-
phatic Contraction to Oscillatory Flow”, Scientific Reports, vol. 9, no. 1, pp. 1–14,
2019.
[134] S. D. Zawieja, W. Wang, X. Wu, Z. V. Nepiyushchikh, D. C. Zawieja, and M.
Muthuchamy, “Impairments in the intrinsic contractility of mesenteric collecting
lymphatics in a rat model of metabolic syndrome”, American Journal of Physiology-
Heart and Circulatory Physiology, vol. 302, no. 3, H643–H653, 2012.
[135] S. Liao, G. Cheng, D. A. Conner, Y. Huang, R. S. Kucherlapati, L. L. Munn, N. H.
Ruddle, R. K. Jain, D. Fukumura, and T. P. Padera, “Impaired lymphatic contrac-
tion associated with immunosuppression”, Proceedings of the National Academy
of Sciences, vol. 113, no. 40, E5992–E5992, 2016.
[136] Y. Liu-Chittenden, B. Huang, J. S. Shim, Q. Chen, S.-J. Lee, R. A. Anders, J. O.
Liu, and D. Pan, “Genetic and pharmacological disruption of the TEAD-YAP com-
plex suppresses the oncogenic activity of YAP”, Genes & Development, vol. 26,
no. 12, pp. 1300–1305, 2012.
[137] K. Brodowska, A. Al-Moujahed, A. Marmalidou, M. Meyer zu Horste, J. Cichy,
J. W. Miller, E. Gragoudas, and D. G. Vavvas, “The clinically used photosensitizer
Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in
80
vitro without light activation”, Experimental Eye Research, vol. 124, pp. 67–73,
2014.
[138] H. Wei, F. Wang, Y. Wang, T. Li, P. Xiu, J. Zhong, X. Sun, and J. Li, “Verteporfin
suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic duc-
tal adenocarcinoma via disrupting the YAP-TEAD complex”, Cancer Science, vol. 108,
no. 3, pp. 478–487, 2017.
[139] H. T. Du, L. L. Du, X. L. Tang, H. Y. Ge, and P. Liu, “Blockade of MMP-2 and
MMP-9 inhibits corneal lymphangiogenesis”, Graefe’s Archive for Clinical and
Experimental Ophthalmology, vol. 255, no. 8, pp. 1573–1579, 2017.
[140] H. Cho, J. Kim, J. H. Ahn, Y.-K. Hong, T. Mäkinen, D.-S. Lim, and G. Y. Koh,
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